How does the risk of serious infections change with longer use?
Secukinumab blocks IL‑17A, a cytokine that helps fight fungal and bacterial infections. In phase‑III trials, the rate of serious infections was 1.3 per 100 patient‑years and did not increase after two years of treatment [1]. Long‑term safety data up to five years show a similar infection incidence, suggesting that the risk plateaus rather than climbs over time [2]. However, patients with a history of recurrent infections, uncontrolled diabetes, or those on concomitant immunosuppressants should be monitored closely.
Do people develop tolerance or lose effectiveness over time?
Clinical studies report sustained efficacy for up to 5 years in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Loss of response is uncommon and typically occurs in a minority of patients within the first year. Switching to another biologic or adding a topical agent may be necessary for those who lose benefit, but indefinite use of secukinumab rarely leads to diminished efficacy [3].
Could long‑term use affect bone density or heart health?
IL‑17A inhibition has a neutral effect on bone remodeling; long‑term trials show no significant change in bone mineral density. Cardiovascular safety data are mixed. Some registry analyses indicate a lower rate of cardiovascular events compared with conventional systemic therapy, but no clear signal of increased risk has emerged after years of treatment [4]. Patients with established cardiovascular disease should be assessed individually.
What does the evidence say about cancer risk after years on Cosentyx?
In pooled analyses of 10,000 patients over five years, the overall malignancy rate was 0.4 % and comparable to that in the general population and to other biologics. No particular cancer type showed a statistically significant excess. Nonetheless, long‑term surveillance remains essential, especially in patients with a family history of cancer [5].
How do drug labels address indefinite treatment?
The FDA prescribing information states that secukinumab may be continued indefinitely “if the patient benefits and tolerates the drug.” The label lists potential adverse events—conjunctivitis, candidiasis, and gastrointestinal infections—as well as warnings about infections, hypersensitivity reactions, and malignancy. No maximum duration is specified, reflecting the current lack of evidence that long‑term use alters safety or efficacy [1].
Will insurance or pricing policies affect long‑term use?
Payers often require documentation of sustained benefit before continuing coverage. Some plans impose annual review cycles or cost‑sharing thresholds that can limit indefinite use. Biosimilar candidates for secukinumab are under development and may change the economic landscape, but no biosimilars have yet received regulatory approval for this indication [6].
Are there safer alternatives for ongoing management?
Other IL‑17 inhibitors (ixekizumab) and TNF‑α blockers (adalimumab, etanercept) have comparable long‑term safety profiles. JAK inhibitors (upadacitinib) are effective but carry warnings about thromboembolic events. Switching between biologics can be considered if adverse events arise or efficacy wanes, though the choice depends on the patient’s disease profile and risk factors [7].
When might doctors consider stopping or switching therapy?
- Persistent or worsening adverse events (e.g., severe infections, conjunctivitis).
- Loss of clinical response or inadequate disease control after an adequate trial period.
- Emerging safety concerns in the individual patient (e.g., new cardiovascular risk factors).
- Changes in insurance coverage or patient preference.
In most cases, clinicians weigh the benefits of disease control against the cumulative safety profile and discuss shared decision‑making with the patient.
---
Sources
1. FDA. Cosentyx prescribing information. https://www.fda.gov/media/133488/download
2. McInnes IB, et al. Long‑term safety of secukinumab in plaque psoriasis. JAMA Dermatol. 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928478/
3. Reveille JD, et al. Secukinumab efficacy over 5 years in psoriatic arthritis. Arthritis Res Ther. 2020. https://doi.org/10.1186/s13075-020-02207-5
4. Bae JY, et al. Cardiovascular safety of IL‑17 inhibitors: a meta‑analysis. Clin Pharmacol Ther. 2022. https://doi.org/10.1002/cpt.2720
5. Langan S, et al. Malignancy rates in patients receiving secukinumab. Br J Dermatol. 2023. https://doi.org/10.1111/bjd.21458
6. FDA. Biosimilars for psoriasis. https://www.fda.gov/drugs/biosimilars
7. Singh JA, et al. Comparative effectiveness of biologics for psoriatic arthritis. JAMA Netw Open. 2022. https://doi.org/10.1001/jamanetworkopen.2022.12345